We are pleased to invite investors and analysts to participate in our virtual event on Tuesday, 8 June 2021, highlighting Roche data presented during the congress scientific program from June 4 – 8 2021.

16:00 – 17:30 CEST / 15:00 - 16:30 BST
10:00 – 11:30 am EDT / 7:00 – 8:30 am PDT

The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 3pm CEST on the day of the event. > click here


Agenda 

  • Early pipeline programs in focus
    William Pao, M.D., Ph.D.,Global Head of Roche Pharma Research and Early Development
    Ira Mellman, Ph.D., Vice President, Cancer Immunology, Genentech Research & Early Development
  • Late-stage pipeline programs in focus
    Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development
  • ASCO 2021 Highlight
    Tecentriq in adjuvant NSCLC: Phase 3 IMpower010 primary results
    Heather Wakelee, M.D., Prof. of Medicine, Stanford University Medical Center / Deputy Director Stanford Cancer Institute
  • Q&A
Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.

Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.

A replay of the webcast will be available via > ir.roche.com

Best regards,

Karl Mahler
Head of Investor Relations and Roche Group Planning

Sabine Borngräber
Investor Relations Officer
Roche Investor Relations  
Dr. Karl Mahler
Phone: +41 61 68-78503
e-mail: karl.mahler@roche.com



  		Jon Kaspar Bayard
Phone: +41 61 68-83894
e-mail: jon_kaspar.bayard@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com



  		Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com 		Dr. Gerard Tobin
Phone: +41 61 68-72942
e-mail: gerard.tobin@roche.com
   
Investor Relations North America  
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com 		 

 

get the latest news and updates to your inbox.